|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Rossi A and Di Maio M: Platinum-based
chemotherapy in advanced non-small-cell lung cancer: Optimal number
of treatment cycles. Expert Rev Anticancer Ther. 16:653–660.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang D, Yang R, Wang S and Dong Z:
Paclitaxel: New uses for an old drug. Drug Des Devel Ther.
8:279–284. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ramalingam S and Belani CP: Paclitaxel for
non-small cell lung cancer. Expert Opin Pharmacother. 5:1771–1780.
2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Joshi M, Liu X and Belani CP: Taxanes,
past, present, and future impact on non-small cell lung cancer.
Anticancer Drugs. 25:571–583. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lu C, Xie Z and Peng Q: MiRNA-107 enhances
chemosensitivity to paclitaxel by targeting antiapoptotic factor
Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873.
2017.PubMed/NCBI
|
|
10
|
Libby P: Interleukin-1 Beta as a target
for atherosclerosis therapy: Biological basis of CANTOS and beyond.
J Am Coll Cardiol. 70:2278–2289. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lopez-Castejon G and Brough D:
Understanding the mechanism of IL-1β secretion. Cytokine Growth
Factor Rev. 22:189–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Arranz L, Arriero MDM and Villatoro A:
Interleukin-1β as emerging therapeutic target in hematological
malignancies and potentially in their complications. Blood Rev.
31:306–317. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Azad N, Rojanasakul Y and Vallyathan V:
Inflammation and lung cancer: Roles of reactive oxygen/nitrogen
species. J Toxicol Environ Health B Crit Rev. 11:1–15.
2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han
SW, Oh DY, Lee SH, Im SA, Kim TY, et al: Clinical implications of
VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell
lung cancer. Cancer Res Treat. 45:325–333. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mendoza-Rodríguez MG, Ayala-Sumuano JT,
García-Morales L, Zamudio-Meza H, Pérez-Yepez EA and Meza I: IL-1β
inflammatory cytokine-induced TP63 isoform ∆NP63α signaling cascade
contributes to cisplatin resistance in human breast cancer cells.
Int J Mol Sci. 20(E270)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Feng X, Luo Q, Zhang H, Wang H, Chen W,
Meng G and Chen F: The role of NLRP3 inflammasome in 5-fluorouracil
resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res.
36(81)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lee CR, Kang JA, Kim HE, Choi Y, Yang T
and Park SG: Secretion of IL-1β from imatinib-resistant chronic
myeloid leukemia cells contributes to BCR-ABL mutation-independent
imatinib resistance. FEBS Lett. 590:358–368. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang X, Srivastava R, Howell SH and
Bassham DC: Activation of autophagy by unfolded proteins during
endoplasmic reticulum stress. Plant J. 85:83–95. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mendoza-Rodríguez M, Arévalo Romero H,
Fuentes-Pananá EM, Ayala-Sumuano JT and Meza I: IL-1β induces
up-regulation of BIRC3, a gene involved in chemoresistance to
doxorubicin in breast cancer cells. Cancer Lett. 390:39–44.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bhat IA, Naykoo NA, Qasim I, Ganie FA,
Yousuf Q, Bhat BA, Rasool R, Aziz SA and Shah ZA: Association of
interleukin 1 beta (IL-1β) polymorphism with mRNA expression and
risk of non small cell lung cancer. Meta Gene. 2:123–133.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lee CH, Chang JS, Syu SH, Wong TS, Chan
JY, Tang YC, Yang ZP, Yang WC, Chen CT, Lu SC, et al: IL-1β
promotes malignant transformation and tumor aggressiveness in oral
cancer. J Cell Physiol. 230:875–884. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang Q, Wang H, Mao C, Sun M, Dominah G,
Chen L and Zhuang Z: Fatty acid oxidation contributes to IL-1β
secretion in M2 macrophages and promotes macrophage-mediated tumor
cell migration. Mol Immunol. 94:27–35. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang C, Wang MW, Tashiro S, Onodera S and
Ikejima T: IL-1beta acts in synergy with endogenous IL-1beta in
A375-S2 human melanoma cell apoptosis through mitochondrial
pathway. J Korean Med Sci. 20:555–561. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Guadagno J, Swan P, Shaikh R and Cregan
SP: Microglia-derived IL-1β triggers p53-mediated cell cycle arrest
and apoptosis in neural precursor cells. Cell Death Dis.
6(e1779)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Matanić D, Beg-Zec Z, Stojanović D,
Matakorić N, Flego V and Milevoj-Ribić F: Cytokines in patients
with lung cancer. Scand J Immunol. 57:173–178. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vikhreva P, Petrova V, Gokbulut T,
Pestlikis I, Mancini M, Di Daniele N, Knight RA, Melino G and
Amelio I: TAp73 upregulates IL-1β in cancer cells: Potential
biomarker in lung and breast cancer? Biochem Biophys Res Commun.
482:498–505. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
d'Amato TA, Landreneau RJ, McKenna RJ,
Santos RS and Parker RJ: Prevalence of in vitro extreme
chemotherapy resistance in resected nonsmall-cell lung cancer. Ann
Thorac Surg. 81:440–446; discussion 446-447. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Voloshin T, Alishekevitz D, Kaneti L,
Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M,
Machluf M, et al: Blocking IL1β Pathway following paclitaxel
chemotherapy slightly inhibits primary tumor growth but promotes
spontaneous metastasis. Mol Cancer Ther. 14:1385–1394.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wong J, Tran LT, Magun EA, Magun BE and
Wood LJ: Production of IL-1β by bone marrow-derived macrophages in
response to chemotherapeutic drugs: Synergistic effects of
doxorubicin and vincristine. Cancer Biol Ther. 15:1395–1403.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Parzych KR and Klionsky DJ: An overview of
autophagy: Morphology, mechanism, and regulation. Antioxid Redox
Signal. 20:460–473. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tanida I and Waguri S: Measurement of
autophagy in cells and tissues. Methods Mol Biol. 648:193–214.
2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Harris J, Lang T, Thomas JPW, Sukkar MB,
Nabar NR and Kehrl JH: Autophagy and inflammasomes. Mol Immunol.
86:10–15. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Claude-Taupin A, Bissa B, Jia J, Gu Y and
Deretic V: Role of autophagy in IL-1β export and release from
cells. Semin Cell Dev Biol. 83:36–41. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36(52)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kumar A, Singh UK and Chaudhary A:
Targeting autophagy to overcome drug resistance in cancer therapy.
Future Med Chem. 7:1535–1542. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu S and Li X: Autophagy inhibition
enhances sensitivity of endometrial carcinoma cells to paclitaxel.
Int J Oncol. 46:2399–2408. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen K and Shi W: Autophagy regulates
resistance of non-small cell lung cancer cells to paclitaxel.
Tumour Biol. 37:10539–10544. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang Z, He R, Xia H, Wei Y and Wu S:
Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity
through inhibition of autophagy. Oncol Lett. 13:3465–3470.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ran X, Yang J, Liu C, Zhou P, Xiao L and
Zhang K: MiR-218 inhibits HMGB1-mediated autophagy in endometrial
carcinoma cells during chemotherapy. Int J Clin Exp Pathol.
8:6617–6626. 2015.PubMed/NCBI
|
